Cargando…

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors

The membrane transport of many cationic prescription drugs depends on facilitated transport by organic cation transporters of which several members, including OCT2 (SLC22A2), are sensitive to inhibition by select tyrosine kinase inhibitors (TKIs). We hypothesized that TKIs may differentially interac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uddin, Muhammad Erfan, Talebi, Zahra, Chen, Sijie, Jin, Yan, Gibson, Alice A., Noonan, Anne M., Cheng, Xiaolin, Hu, Shuiying, Sparreboom, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707461/ https://www.ncbi.nlm.nih.gov/pubmed/34959286 http://dx.doi.org/10.3390/pharmaceutics13122004

Ejemplares similares

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
por: Hu, S, et al.
Publicado: (2014)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
por: Hu, S, et al.
Publicado: (2017)

Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity
por: Nepal, Mahesh R., et al.
Publicado: (2022)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation
por: Li, Yang, et al.
Publicado: (2021)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1
por: Omote, Saki, et al.
Publicado: (2018)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo
por: Yu, Tao, et al.
Publicado: (2021)

Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor
por: Yang, Yuqi, et al.
Publicado: (2020)

Chk-mate on resistance to kinase inhibitors
por: Shapiro, Paul
Publicado: (2018)

Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy
por: Stage, Tore B., et al.
Publicado: (2020)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Predicting Paclitaxel Disposition in Humans With Whole‐Body Physiologically‐Based Pharmacokinetic Modeling
por: Fu, Qiang, et al.
Publicado: (2019)

The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
por: Eom, Keun-Yong, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
por: Futosi, Krisztina, et al.
Publicado: (2023)

Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo
por: Klenke, Frank M, et al.
Publicado: (2007)

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
por: McLeod, H. L., et al.
Publicado: (1996)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
por: Cho, Hyewon, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
por: van Leeuwen, Roelof W. F., et al.
Publicado: (2017)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A
por: Bourn, Jennifer, et al.
Publicado: (2019)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.
por: Gillespie, J., et al.
Publicado: (1993)

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro
por: Skoglund, Karin, et al.
Publicado: (2013)

Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
por: Bourn, Jennifer, et al.
Publicado: (2018)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
por: Aiebchun, Thitinan, et al.
Publicado: (2021)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016)

DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia
por: Buelow, Daelynn R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jdg80gajkjos4rq9ed4j2tgvvg